近期,强生、罗氏、礼来等多家跨国药企相继披露2025年业绩。其中,JNJ" target="_blank" web="1">强生以942亿美元总营收位居首位,罗氏凭借五大重磅药物获得744.3亿美元收入,位居第二;得益于替尔泊肽双靶点减肥药,礼来以651.79亿美元挤进前三,成为2025年业绩榜最大黑马。 总体看,大部分跨国药企业绩实现了稳定增长,部分明星药品对业绩影响较大。业内人士认为,专利...
Source Link近期,强生、罗氏、礼来等多家跨国药企相继披露2025年业绩。其中,JNJ" target="_blank" web="1">强生以942亿美元总营收位居首位,罗氏凭借五大重磅药物获得744.3亿美元收入,位居第二;得益于替尔泊肽双靶点减肥药,礼来以651.79亿美元挤进前三,成为2025年业绩榜最大黑马。 总体看,大部分跨国药企业绩实现了稳定增长,部分明星药品对业绩影响较大。业内人士认为,专利...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.